Jyao
2021-08-03
Comment
Eli Lilly's stock falls after profit comes up short of expectations, while revenue beat
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":807048911,"tweetId":"807048911","gmtCreate":1627992057433,"gmtModify":1633754596476,"author":{"id":4087362794409800,"idStr":"4087362794409800","authorId":4087362794409800,"authorIdStr":"4087362794409800","name":"Jyao","avatar":"https://static.tigerbbs.com/07173c637c1f024d34616356738353f6","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Comment</p></body></html>","htmlText":"<html><head></head><body><p>Comment</p></body></html>","text":"Comment","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/807048911","repostId":2156405711,"repostType":4,"repost":{"id":"2156405711","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627987440,"share":"https://www.laohu8.com/m/news/2156405711?lang=&edition=full","pubTime":"2021-08-03 18:44","market":"us","language":"en","title":"Eli Lilly's stock falls after profit comes up short of expectations, while revenue beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2156405711","media":"Dow Jones","summary":"(Update: August 3, 2021 at 07:32 a.m. ET)\n(August 3) Shares of Eli Lilly & Co. $(LLY)$ fell 1.67% in","content":"<p><i>(Update: August 3, 2021 at 07:32 a.m. ET)</i></p>\n<p>(August 3) Shares of Eli Lilly & Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a> fell 1.67% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an excess inventory charge related to COVID-19 antibodies. </p>\n<p><img src=\"https://static.tigerbbs.com/2fb579887f37c9856ee6e87861fb3fd4\" tg-width=\"946\" tg-height=\"633\" width=\"100%\" height=\"auto\"></p>\n<p>Net income slipped to $1.39 billion, or $1.53 a share, from $1.41 billion, or $1.55 a share, in the year-ago period. </p>\n<p>Excluding nonrecurring items, adjusted earnings per share rose to $1.87 from $1.45, but was below the FactSet consensus of $1.89. Revenue grew 23% to $6.74 billion, above the FactSet consensus of $6.60 billion, with revenue from its largest drug Trulicity rising 25% to $1.54 billion to top expectations of $1.51 billion. </p>\n<p>Gross margin as a percentage or revenue fell to 71.0% from 77.8%. </p>\n<p>\"As the COVID-19 pandemic has continued to evolve during the second quarter of 2021, Lilly incurred excess inventory charges primarily due to the combination of changes to current and forecasted demand from U.S. and international governments and near-term expiry dates of COVID-19 antibodies,\" the company said in a statement. </p>\n<p>Lilly estimates the COVID-19 pandemic hurt revenue by about $200 million in the U.S. and $50 million outside the U.S. For 2021, the company expects adjusted EPS of $7.80 to $8.00, surrounding the FactSet consensus of $7.89. </p>\n<p>The stock has soared 46.1% year to date through Monday, while the S&P 500 has gained 16.8%.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly's stock falls after profit comes up short of expectations, while revenue beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly's stock falls after profit comes up short of expectations, while revenue beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-03 18:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><i>(Update: August 3, 2021 at 07:32 a.m. ET)</i></p>\n<p>(August 3) Shares of Eli Lilly & Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a> fell 1.67% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an excess inventory charge related to COVID-19 antibodies. </p>\n<p><img src=\"https://static.tigerbbs.com/2fb579887f37c9856ee6e87861fb3fd4\" tg-width=\"946\" tg-height=\"633\" width=\"100%\" height=\"auto\"></p>\n<p>Net income slipped to $1.39 billion, or $1.53 a share, from $1.41 billion, or $1.55 a share, in the year-ago period. </p>\n<p>Excluding nonrecurring items, adjusted earnings per share rose to $1.87 from $1.45, but was below the FactSet consensus of $1.89. Revenue grew 23% to $6.74 billion, above the FactSet consensus of $6.60 billion, with revenue from its largest drug Trulicity rising 25% to $1.54 billion to top expectations of $1.51 billion. </p>\n<p>Gross margin as a percentage or revenue fell to 71.0% from 77.8%. </p>\n<p>\"As the COVID-19 pandemic has continued to evolve during the second quarter of 2021, Lilly incurred excess inventory charges primarily due to the combination of changes to current and forecasted demand from U.S. and international governments and near-term expiry dates of COVID-19 antibodies,\" the company said in a statement. </p>\n<p>Lilly estimates the COVID-19 pandemic hurt revenue by about $200 million in the U.S. and $50 million outside the U.S. For 2021, the company expects adjusted EPS of $7.80 to $8.00, surrounding the FactSet consensus of $7.89. </p>\n<p>The stock has soared 46.1% year to date through Monday, while the S&P 500 has gained 16.8%.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156405711","content_text":"(Update: August 3, 2021 at 07:32 a.m. ET)\n(August 3) Shares of Eli Lilly & Co. $(LLY)$ fell 1.67% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an excess inventory charge related to COVID-19 antibodies. \n\nNet income slipped to $1.39 billion, or $1.53 a share, from $1.41 billion, or $1.55 a share, in the year-ago period. \nExcluding nonrecurring items, adjusted earnings per share rose to $1.87 from $1.45, but was below the FactSet consensus of $1.89. Revenue grew 23% to $6.74 billion, above the FactSet consensus of $6.60 billion, with revenue from its largest drug Trulicity rising 25% to $1.54 billion to top expectations of $1.51 billion. \nGross margin as a percentage or revenue fell to 71.0% from 77.8%. \n\"As the COVID-19 pandemic has continued to evolve during the second quarter of 2021, Lilly incurred excess inventory charges primarily due to the combination of changes to current and forecasted demand from U.S. and international governments and near-term expiry dates of COVID-19 antibodies,\" the company said in a statement. \nLilly estimates the COVID-19 pandemic hurt revenue by about $200 million in the U.S. and $50 million outside the U.S. For 2021, the company expects adjusted EPS of $7.80 to $8.00, surrounding the FactSet consensus of $7.89. \nThe stock has soared 46.1% year to date through Monday, while the S&P 500 has gained 16.8%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":447,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/807048911"}
精彩评论